Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

Diabetes Care(2023)10.2337/dc23-0492Source: DataRank Database

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes is a research paper published in Diabetes Care (2023). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.12)OA: bronzeTopics (59)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

David D. Berg ORCID,Andrea Bellavia ORCID,Jamie P. Dwyer ORCID,Ofri Mosenzon ORCID,Benjamin M. Scirica ORCID

Live enrichment

PubMed:37556796 PMC:PMC10516252 OpenAlex:https://openalex.org/W4385693606

American Heart Association

Grant: Cardiometabolic Health & Type 2 Diabetes Mellitus

NHLBI NIH HHS

Grant: T32 HL007604

American Heart Association

Grant: Cardiometabolic Health & Type 2 Diabetes Mellitus

American Heart Association-American Stroke Association

Grant: 20SFRN35120087

National Institutes of Health

Grant: 2T32HL007604-06

TRAINING PROGRAM IN CARDIOVASCULAR RESEARCH

Brigham and Women’s Hospital

FWCI

2.12

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

bronzeLicense: https://www.diabetesjournals.org/journals/pages/license

journalhttps://diabetesjournals.org/care/article-pdf/46/10/1807/734864/dc230492.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/46/10/1807/734864/dc230492.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/doi/10.2337/dc23-0492/734864/dc230492.pdf

journalhttps://doi.org/10.2337/dc23-0492

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37556796

Fields of Study

Diabetes Treatment and ManagementChronic Kidney Disease and DiabetesHyperglycemia and glycemic control in critically ill and hospitalized patients03 medical and health sciences0302 clinical medicineHumansBenzhydryl CompoundsDiabetes Mellitus, Type 2Disease ProgressionGlomerular Filtration RateKidneyMyocardial InfarctionRenal Insufficiency, ChronicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsGlucosides

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsDiabetes Mellitus, Type 2Glomerular Filtration RateGlucosidesHumansKidneyMyocardial InfarctionDisease ProgressionRisk AssessmentSodium-Glucose Transporter 2Renal Insufficiency, Chronic

Keywords

MedicineDapagliflozinKidney diseaseInternal medicineType 2 diabetesRenal functionGlycated hemoglobinTIMIMyocardial infarctionFramingham Risk ScoreDiabetes mellitusHazard ratioCreatinineEndocrinologyDiseasePercutaneous coronary interventionConfidence intervalKidneyRisk AssessmentDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2GlucosidesDisease ProgressionHumansCardiology (incl. cardiovascular diseases)Original ArticleBenzhydryl CompoundsRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsGlomerular Filtration Rate

Sustainable Development Goals

SDG 0: Good health and well-being